Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AMLCAMBRIDGE, ...

Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan Ther ...
The Caledonian-Record

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell ...

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML ...

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine)

IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatenin ...

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, will participate in a webcast ...

FDA Grants INTERACT Meeting for Lead Fabry Disease Program at Glafabra Therapeutics

S03, a cell-based gene therapy designed to replace 130 lifetime Fabry infusions with a single procedure. FDA’s acceptance of INTERACT request validates the clinical and manufacturing case built on ...
Becker's Hospital Review

Supreme Court lets Medicare drug price negotiations stand: What it means for health systems

The U.S. Supreme Court has declined to hear petitions from six major drugmakers challenging the Medicare Drug Price Negotiation Program, leaving in place lower court rulings that upheld the program ...

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a ...

First MVID patient enters the active treatment only extension phase after completion of randomized double-blind ...

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

HIGHLIGHTS New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational studyFocus on investigating new, daily dosing of narmafotinib in ...
PharmiWeb

Egetis to Present Healthcare Resource Drivers and Cost in MCT8 Deficiency at ISPOR 2026

STOCKHOLM, SE / ACCESS Newswire / May 19, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX)(NASDAQ Stockholm:EGTX) today announced its participation in the annual conference ...
Medindia

Myosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-muscle Myosin II in Newly Diagnosed Glioblastoma

Myosin Therapeutics, a clinical stage biotechnology company developing innovative therapies for oncology, today announced that the first patient has been dosed in its Phase 1/2 STAR-GBM study. The ...

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with ...